Contraindicated (1)bortezomib will raise the stage or influence of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors could enhance mavacamten systemic publicity, causing heart failure resulting from systolic dysfunction.Unlock 38% more drug discovery time and do away with decision-ea